Last updated: Aug 26, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07102381 | 2 | A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | HER2 -- bispecific antibody |
| NCT05827081 | 3 | Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | CDK4/6 -- cyclin-dependent kinase 4/6 inhibitor |
| NCT05894239 | 3 | A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer | PI3K + HER2 -- PI3K inhibitor + anti-HER2 antibody combination |
| NCT06545682 | 1 | Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) | PI3K alpha + PD-1 -- PI3K alpha inhibitor + immune checkpoint inhibitor |
| NCT06067503 | 2 | Biomarkers to Detect Endocrine Therapy Resistance | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| Fudan University | 110 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 39 |
| Memorial Sloan Kettering Cancer Center | 36 |
| Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 29 |
| The First Affiliated Hospital with Nanjing Medical University | 28 |
Countries/regions with the most active trial sites for breast cancer. A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Jun 2027 | NCT04861077 | Monitoring Breast Cancer Immunotherapy Treatment With Advanced Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) | Tumor hypoxia -- 18F-fluoromisonidazole PET with MRI (diagnostic imaging) |
| Dec 2026 | NCT07785856 | Study of Trastuzumab Deruxtecan (T-DXd) in Combination With a RAGE Inhibitor in Patients With T-DXd-Resistant HER2-Positive or HER2-Low Metastatic Breast Cancer | HER2 + RAGE -- antibody-drug conjugate (T-DXd) combined with RAGE inhibitor |
| Nov 2026 | NCT07730125 | Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies | Regulatory T cells -- gene-edited cell therapy |
| Oct 30, 2026 | NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | LRRC15 -- radiolabeled monoclonal antibody (radioimmunotherapy) |
| Oct 1, 2026 | NCT07553390 | Phase 1b Study Of TRICK-NK In Combination With T-Dxd In Treatment-Refractory Breast Cancers | TGFBR2 -- knockout; TROP2 -- chimeric antigen receptor (CAR) NK cells; HER2 -- antibody-drug conjugate (trastuzumab deruxtecan) |
| Oct 2026 | NCT07581314 | Oral Zn-Telomir Monotherapy in Patients With Advanced or Metastatic Triple-Negative Breast Cancer (TNBC) | Telomerase -- inhibitor (Zn-Telomir) |
| Sep 15, 2026 | NCT06148038 | CBD for Breast Cancer Primary Tumors | Cannabinoid receptor -- cannabinoid receptor agonist (CBD) |
| Sep 2026 | NCT07545122 | A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers | Nectin-4 -- bispecific antibody (CT-202) |
You've seen the breast cancer landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.